TriSalus Life Sciences
TriSalus Life Sciences® was established to develop and commercialize disruptive drug delivery technology for the treatment of liver and pancreatic tumors. Our proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach, which has been used in over 18,000 procedures, improves therapy penetration by modulating pressure and flow to overcome the intravascular barriers to therapy delivery. This is a significant step forward in the treatment of liver and pancreatic tumors.
Along with effective drug delivery, we recognize that overcoming immunosuppression in these organs is also important to successful immunotherapy. Because of this, we’ve launched a platform approach that integrates our innovative device technology with a proprietary therapeutic. In 2020 we acquired nelitolimod, an investigational toll-like receptor 9 (TLR9) agonist with the goal of improving outcomes for liver and pancreatic cancer patients. In our phase 1 studies, nelitolimod has demonstrated reversal of immunosuppression and promotion of responses to checkpoint inhibitors.1,2,3,4
In addition to our in-market TriNav® Infusion System and our 510(k) cleared pancreatic delivery system, we are now moving forward with a range of Phase 1 clinical trials in primary liver and pancreatic cancers. We believe we have the potential to transform the treatment of these diseases for patients with limited treatment options.